Literature DB >> 24713673

Elevated pancreatic polypeptide levels in pancreatic neuroendocrine tumors and diabetes mellitus: causation or association?

Jessica E Maxwell1, Thomas M O'Dorisio, Andrew M Bellizzi, James R Howe.   

Abstract

Pancreatic neuroendocrine tumors (PNETs) that secrete primarily pancreatic polypeptide (PP) are rare and usually nonfunctional. There are approximately 2 dozen reports of PP-secreting PNETs, 3 of which have been associated with diabetes mellitus (DM). None suggest a mechanism for the association between PP-secreting PNETs and DM. We describe 5 patients with PP-producing tumors who were diagnosed with DM at the same time as their PNETs, review the literature on PP, and consider its role in the pathophysiology of DM. The cases discussed were extracted from our surgical neuroendocrine tumor database. We examined all patients with PP-predominant PNETs--both with DM (n = 5) and without (n = 8). The 5 patients with DM at the time of PNET diagnosis demonstrated improvement or resolution of their DM postoperatively. In the patients with PP-secreting PNETs but no diagnosis of DM preoperatively, 1 became hypoglycemic postoperatively, and 2 others developed postoperative DM. The 5 cases discussed in detail raise the question of whether the hypersecretion of PP in PNETs might be an important event leading to the development of DM. Although the literature does not provide a mechanism for this association, it may be related to the role of PP in hepatic glucose regulation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24713673      PMCID: PMC4268541          DOI: 10.1097/MPA.0000000000000082

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  20 in total

Review 1.  Somatostatinomas, PPomas, neurotensinomas.

Authors:  A I Vinik; W E Strodel; F E Eckhauser; A R Moattari; R Lloyd
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

2.  Metastatic pancreatic polypeptide producing tumour presenting with diabetes mellitus.

Authors:  J D Quin; D A Marshall; B M Fisher; A C MacCuish
Journal:  Scott Med J       Date:  1991-10       Impact factor: 0.729

3.  Carbohydrate digestion and release of pancreatic polypeptide in health and diabetes mellitus.

Authors:  P Layer; V L Go; E P DiMagno
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

4.  Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man.

Authors:  N E Seymour; F C Brunicardi; R L Chaiken; H E Lebovitz; R E Chance; R L Gingerich; D Elahi; D K Andersen
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982

5.  Pancreatic-polypeptide (PP) and endocrine tumours of the pancreas.

Authors:  T W Schwartz
Journal:  Scand J Gastroenterol Suppl       Date:  1979

6.  Somatostatinoma syndrome accompanied by overproduction of pancreatic polypeptide.

Authors:  C Nakanome; M Koizumi; H Fujiya; H Akai; T Toyota; Y Goto; J Kameyama; K Miyakawa; K Hanew
Journal:  Tohoku J Exp Med       Date:  1984-02       Impact factor: 1.848

7.  Vagal, cholinergic regulation of pancreatic polypeptide secretion.

Authors:  T W Schwartz; J J Holst; J Fahrenkrug; S L Jensen; O V Nielsen; J F Rehfeld; O B de Muckadell; F Stadil
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

8.  Reversal of abnormal glucose metabolism in chronic pancreatitis by administration of pancreatic polypeptide.

Authors:  Y S Sun; F C Brunicardi; P Druck; S Walfisch; S A Berlin; R E Chance; R L Gingerich; D Elahi; D K Andersen
Journal:  Am J Surg       Date:  1986-01       Impact factor: 2.565

9.  Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus.

Authors:  W J Pories; M S Swanson; K G MacDonald; S B Long; P G Morris; B M Brown; H A Barakat; R A deRamon; G Israel; J M Dolezal
Journal:  Ann Surg       Date:  1995-09       Impact factor: 12.969

10.  Pancreatic polypeptide and calcitonin secretion from a pancreatic tumour-clinical improvement after hepatic artery embolization.

Authors:  A Manche; S M Wood; T E Adrian; R B Welbourn; S R Bloom
Journal:  Postgrad Med J       Date:  1983-05       Impact factor: 2.401

View more
  6 in total

1.  Incidence and Risk Factors for New-Onset Diabetes Mellitus After Surgical Resection of Pancreatic Cystic Lesions: A MarketScan Study.

Authors:  Stephen A Firkins; Phil A Hart; Kyle Porter; ChienWei Chiang; Jordan M Cloyd; Mary Dillhoff; Luis F Lara; Andrei Manilchuk; Georgios I Papachristou; Timothy M Pawlik; Allan Tsung; Darwin L Conwell; Somashekar G Krishna
Journal:  Pancreas       Date:  2022-07-19       Impact factor: 3.243

Review 2.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

Review 3.  Endocrinopathy and Aging in Ferrets.

Authors:  V Bakthavatchalu; S Muthupalani; R P Marini; J G Fox
Journal:  Vet Pathol       Date:  2016-03       Impact factor: 2.221

4.  Metformin use and young age lung cancer: A case series report.

Authors:  B O Deng; Y I Wang; Dong Xie; Shawn M Stoddard; Ping Yang
Journal:  Oncol Lett       Date:  2016-03-08       Impact factor: 2.967

5.  Hypoglycemia in a Patient With a Polyhormonal Pancreatic Neuroendocrine Tumor With Evidence of Endocrine Progenitors.

Authors:  Zachary B Simons; Rachel C Morgan; Laurel Rose; Jennifer B Nelson; Sarah A Tersey; Raghavendra G Mirmira
Journal:  J Endocr Soc       Date:  2018-01-16

Review 6.  PPoma Review: Epidemiology, Aetiopathogenesis, Prognosis and Treatment.

Authors:  Thais Ligiero Braga; Ralph Santos-Oliveira
Journal:  Diseases       Date:  2018-01-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.